Minglei Zhuo

12PUBLICATIONS
17CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 26, 2026
Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression.

|Aug 11, 2025
Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial.

Huiyang Shi, Miaohan Wang, Junling Li

|Jun 26, 2024
Women patients with small-cell lung cancer using immunotherapy in a real-world cohort achieved long-term survival.

Yuling He, Lingdong Kong, Xumeng Ji

|Feb 08, 2024
Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis.

Hanxiao Chen, Xiangjuan Ma, Jie Liu

|Mar 13, 2020
Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.

Shuhang Wang, Qiuping Liang, Yujia Chi

|Nov 08, 2019
The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.

Minglei Zhuo, Yanfang Guan, Xue Yang

Pageof 2

Frequent Collaborators

6 joint publications

Ziping Wang

4 joint publications

Jia Zhong

4 joint publications

Xue Yang

3 joint publications

Wenting Chen